[Orthostatic hypotension following cyclazenine medication].
D000804:Angiotensin II / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects*; D004562:Electrocardiography; D004877:Ergoloid Mesylates / Q000627:therapeutic use; D004878:Ergotamine / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007024:Hypotension, Orthostatic / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D009638:Norepinephrine / Q000627:therapeutic use; D008517:Phytotherapy; D010880:Piperidines / Q000009:adverse effects*; D010946:Plants, Medicinal; D011654:Pulmonary Edema / Q000150:complications; D011926:Rauwolfia / Q000627:therapeutic use; D013565:Sympatholytics / Q000627:therapeutic use
D000959:Antihypertensive Agents; D010880:Piperidines; D013565:Sympatholytics; D000804:Angiotensin II; D008750:Methyldopa; D004877:Ergoloid Mesylates; D004878:Ergotamine; D009638:Norepinephrine
Orthostatische Hypotonie nach Cyclazenin-Medikation.